S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
CABA · Cabaletta Bio, Inc.
NASDAQ NMS - GLOBAL MARKET - Real Time Price • USD
Cabaletta Bio Inc (CABA)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$1.53
-0.07
(-4.36%)
● At close: October 21 at 4:00:00 PM EDT
$1.54
+0.00
(+0.00%)
After-Hours:
4:01:30 PM EDT
DAY'S RANGE
$1.53
$1.51
$1.63
52-WEEK RANGE
$1.53
$1.39
$4.23
What's happening
- CABA is down 4.36% today, trading at $1.53. — Live quote
- Volume today (235,391) is well below its 3-month average of 5,234,140. (Finnhub fundamentals)
- Reports earnings on 2026-11-09 (before market open), 18 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-0.34 actual vs. $-0.38 estimated (+10.7%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 6
Buy 7
Hold 3
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (16 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
CABA
-26.48%
vs S&P 500
-39.26%
1-YEAR RETURN
CABA
-42.91%
vs S&P 500
-57.47%
6-MONTH RETURN
CABA
-54.26%
3-MONTH RETURN
CABA
-42.91%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-0.34
Est. $-0.38
BEAT +10.7%
2026-04-26 (Q1 2026)
$-0.39
Est. $-0.41
BEAT +4.8%
2026-01-26 (Q4 2025)
$-0.40
Est. $-0.47
BEAT +14.9%
2025-10-26 (Q3 2025)
$-0.44
Est. $-0.48
BEAT +8.6%
Valuation Measures & Ratios
Enterprise Value4$68.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book72.41
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-128.27%
Return on Assets (ROA9)-95.47%
Avg Volume (3M)5,234,140
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $468.2M | $299.6M | $238.1M | $94.9M | $70.1M |
| P/E | -2.54 | -1.77 | -1.52 | -0.68 | -0.59 |
| Price/Book | 2.22 | 2.90 | 1.71 | 0.53 | 0.58 |
| ROE | -87.62% | -164.03% | -112.26% | -78.05% | -98.08% |
| ROA | -71.88% | -114.38% | -82.51% | -62.05% | -72.19% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short38,613,761
Change from Prior Settlement+15.87%
% of Float—
Days to Cover (Short Ratio)6.30
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-14; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -42.9%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on CABA
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$52.0M | -$44.3M | -$46.6M | -$45.9M | -$37.1M | -$33.0M | -$30.3M | -$28.0M |
| Net income | -$51.0M | -$43.5M | -$44.9M | -$45.1M | -$35.9M | -$30.6M | -$27.6M | -$25.0M |
| EPS (diluted) | $-0.34 | $-0.39 | $-0.44 | $-0.73 | $-0.71 | $-0.62 | $-0.56 | $-0.51 |
| EPS (basic) | $-0.34 | $-0.39 | $-0.44 | $-0.73 | $-0.71 | $-0.62 | $-0.56 | $-0.51 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $256.7M | $148.1M | $165.1M | $189.8M | $224.5M | $165.1M | $185.0M | $204.4M |
| Total liabilities | $46.1M | $44.8M | $53.0M | $50.3M | $46.0M | $43.6M | $32.7M | $30.2M |
| Stockholders' equity | $210.6M | $103.3M | $112.1M | $139.5M | $178.5M | $121.6M | $152.3M | $174.2M |
| Total current assets | $231.0M | $122.3M | $138.9M | $164.6M | $198.4M | $134.6M | $166.7M | $185.5M |
| Total current liabilities | $39.9M | $41.5M | $50.2M | $45.7M | $41.5M | $34.0M | $27.1M | $22.9M |
| Cash & equivalents | $225.1M | $116.6M | $83.0M | $60.2M | $145.6M | $131.8M | $164.0M | $170.6M |
| Marketable securities (current) | $0 | $0 | $50.6M | $99.7M | $49.1M | — | $0 | $12.4M |
| Marketable securities (non-current) | — | — | — | — | — | — | — | — |
| Property, plant & equipment | $1.5M | $1.6M | $1.9M | $2.1M | $2.4M | $2.6M | $2.7M | $2.8M |
| Other non-current assets | $6.2M | $5.3M | $5.2M | $3.6M | $2.5M | $2.4M | $2.3M | $2.5M |
| Accounts payable | $5.8M | $6.4M | $6.6M | $8.3M | $7.2M | $6.5M | $4.9M | $2.2M |
| Other current liabilities | $60.0K | $90.0K | $80.0K | $30.0K | $16.0K | $50.0K | $40.0K | $30.0K |
| Common stock & paid-in capital | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $1.0K | $0 |
| Retained earnings | -$611.5M | -$560.5M | -$517.0M | -$475.0M | -$430.2M | -$385.0M | -$349.1M | -$316.5M |
| Accumulated other comprehensive income (loss) | $0 | $0 | $25.0K | $23.0K | $1.0K | — | $0 | $1.0K |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$41.5M | -$42.6M | -$35.3M | -$34.5M | -$30.4M | -$30.8M | -$23.1M | -$20.3M |
| Investing cash flow | $0 | $51.0M | $49.8M | -$50.1M | -$49.2M | -$785.0K | $12.1M | $12.2M |
| Financing cash flow | $150.0M | $25.3M | $8.3M | -$806.0K | $93.4M | -$552.0K | $4.4M | $71.0K |
| Free cash flow | -$41.5M | -$42.6M | -$35.5M | -$34.6M | -$30.6M | -$31.6M | -$23.5M | -$20.6M |
| Capital expenditures | $0 | $0 | $205.0K | $78.0K | $161.0K | $785.0K | $376.0K | $253.0K |
| Share-based compensation | $5.5M | $5.3M | $4.3M | $5.8M | $5.7M | $5.2M | $5.4M | $5.2M |
| Change in accounts payable | -$908.0K | -$269.0K | -$1.7M | $1.1M | $595.0K | $1.6M | $2.7M | -$2.0M |
| Purchases of investments | $0 | — | $0 | $50.0M | $49.0M | — | $0 | $0 |
| Sales/maturities of investments | $0 | $51.0M | $50.0M | $0 | $0 | $0 | $12.5M | $12.5M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$172.2M | -$125.1M | -$74.7M | -$54.1M | -$46.3M |
| Net income | -$167.9M | -$115.9M | -$67.7M | -$53.0M | -$46.3M |
| EPS (diluted) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 |
| EPS (basic) | $-2.10 | $-2.34 | $-1.65 | $-1.81 | $-1.80 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $165.1M | $185.0M | $253.7M | $117.0M | $126.3M |
| Total liabilities | $53.0M | $32.7M | $17.5M | $12.4M | $8.4M |
| Stockholders' equity | $112.1M | $152.3M | $236.2M | $104.5M | $118.0M |
| Total current assets | $138.9M | $166.7M | $244.5M | $108.8M | $124.5M |
| Total current liabilities | $50.2M | $27.1M | $16.0M | $9.5M | $8.4M |
| Cash & equivalents | $83.0M | $164.0M | $193.2M | $81.6M | $122.2M |
| Marketable securities (current) | $50.6M | $0 | $48.0M | $24.9M | $0 |
| Property, plant & equipment | $1.9M | $2.7M | $2.5M | $2.6M | $1.4M |
| Other non-current assets | $5.2M | $2.3M | $1.7M | $565.0K | $357.0K |
| Accounts payable | $6.6M | $4.9M | $4.5M | $2.5M | $2.3M |
| Other current liabilities | $80.0K | $40.0K | $40.0K | $39.0K | $54.0K |
| Common stock & paid-in capital | $1.0K | $1.0K | $0 | $0 | $0 |
| Retained earnings | -$517.0M | -$349.1M | -$233.2M | -$165.6M | -$112.6M |
| Accumulated other comprehensive income (loss) | $25.0K | $0 | $39.0K | -$47.0K | $0 |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$131.1M | -$88.2M | -$53.5M | -$46.4M | -$34.1M |
| Investing cash flow | -$50.3M | $47.3M | -$22.5M | -$27.2M | $6.0M |
| Financing cash flow | $100.3M | $11.7M | $187.6M | $33.0M | $48.9M |
| Free cash flow | -$132.3M | -$90.4M | -$54.2M | -$48.8M | -$35.3M |
| Capital expenditures | $1.2M | $2.2M | $687.0K | $2.5M | $1.2M |
| Share-based compensation | $20.9M | $19.5M | $11.3M | $6.9M | $5.8M |
| Change in accounts payable | $1.6M | $1.0M | $1.7M | -$28.0K | $975.0K |
| Purchases of investments | $99.0M | $0 | $84.3M | $49.8M | $0 |
| Sales/maturities of investments | $50.0M | $49.5M | $62.5M | $25.0M | $7.2M |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding CABA as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-01-21 to 2026-01-21
Recent transactions
- Most recent: Chang David J. (Chief Medical Officer) — Open market purchase of 8,800 shares on 2026-01-21.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Chang David J. | Chief Medical Officer | Open market purchase | 2026-01-21 | 8,800 |
| Binder Gwendolyn | President, Science & Tech. | Open market purchase | 2026-01-21 | 11,312 |
| Tomasello Shawn | Reporting person | Open market purchase | 2026-01-21 | 22,725 |
| Gavel Steve | Chief Commercial Officer | Open market purchase | 2026-01-21 | 22,170 |
| Bollard Catherine | Reporting person | Open market purchase | 2026-01-21 | 4,405 |
| Nichtberger Steven | President & CEO | Open market purchase | 2026-01-21 | 45,000 |
| Simon Mark | Reporting person | Open market purchase | 2026-01-21 | 11,061 |
| Gerard Michael | General Counsel | Open market purchase | 2026-01-21 | 6,600 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-01-21 | Chang David J. | Chief Medical Officer | Open market purchase | 8,800 | $2.26 |
| 2026-01-21 | Binder Gwendolyn | President, Science & Tech. | Open market purchase | 11,312 | $2.19 |
| 2026-01-21 | Tomasello Shawn | Reporting person | Open market purchase | 22,725 | $2.21 |
| 2026-01-21 | Gavel Steve | Chief Commercial Officer | Open market purchase | 22,170 | $2.27 |
| 2026-01-21 | Bollard Catherine | Reporting person | Open market purchase | 4,405 | $2.27 |
| 2026-01-21 | Nichtberger Steven | President & CEO | Open market purchase | 45,000 | $2.24 |
| 2026-01-21 | Simon Mark | Reporting person | Open market purchase | 11,061 | $2.28 |
| 2026-01-21 | Gerard Michael | General Counsel | Open market purchase | 6,600 | $2.27 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-21 22:51 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-14 | 8-K | 2026-09-14 | View on SEC.gov → |
| 2026-08-13 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-13 | 8-K | 2026-08-13 | View on SEC.gov → |
| 2026-06-11 | 8-K | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-10 | 4 | 2026-06-09 | View on SEC.gov → |
| 2026-06-03 | 8-K | 2026-06-03 | View on SEC.gov → |
| 2026-05-14 | 10-Q | 2026-03-31 | View on SEC.gov → |
| 2026-05-14 | 8-K | 2026-05-14 | View on SEC.gov → |
Recent news
Headlines about CABA (Cabaletta Bio, Inc.). Links open the publisher — we don’t host full articles.
-
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,SRBK,LUCK,PCF,GAIA,CFBK,MDRR,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,ZBIO,HYPD,ALT,SELF,ENTX,SRBK,PCF,LUCK,GAIA,CFBK,MDRR,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,ZBIO,HYPD,ALT,SELF,ENTX,SRBK,LUCK,PCF,CFBK,MDRR,GAIA,GEF-B,SPMC,MDBH,FRD,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,BLIN,LUCK,PCF,CFBK,MDRR,GAIA,VSTS,GEF-B,SPMC,MDBH,FRD,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-21 -
CABA Jan 2029 1.500 put (CABA290119P00001500) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-20 -
CABA,PFX,ELUT,HYPD,ZBIO,ALT,SELF,ENTX,BLIN,PCF,LUCK,CFBK,MDRR,GAIA,VSTS,SPMC,GEF-B,FRD,MDBH,IRIX,RAL,AIRJ,RNXT | Stock Prices | Quote Comparison - Yahoo Finance
Yahoo! Finance Canada · 2026-10-20 -
CABA,TRIN,RPC,FFIN,NXRT,AVBC,GO,BLCO,CULP,ALT,VSNT,FRST,ENTX,GRNT,BLIN,SSP,GAIA,AFCG,NRGV,APCX,KLTR,THRY | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-20 -
CABA,RPC,TRIN,FFIN,AVBC,GO,NXRT,BLCO,CULP,ALT,VSNT,FRST,ENTX,BLIN,GRNT,SSP,GAIA,NRGV,AFCG,APCX,KLTR,THRY | Stock Prices | Quote Comparison
Yahoo! Finance Canada · 2026-10-19
No headlines in this category right now — try “All”.